secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elevation Oncology, Inc. (—)
CIK:        0001783032
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001104659-25-057620
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elevation Oncology to be acquired by Concentra for $0.36/share plus CVR; CEO Ferra out
--------------------------------------------------------------------------------

- Merger with Concentra Biosciences: $0.36 cash per share plus contingent value right (CVR) for up to 80% of net proceeds from EO-1022.
- Board unanimously recommends tender; closing requires minimum $26.4M net cash and tender of >50% of outstanding shares.
- CEO Joseph Ferra terminated effective June 30; CFO Tammy Furlong appointed President and Interim CEO, receives $600K transaction bonus at closing.
- Stockholders approved reverse stock split (1:10–1:50), ratified auditor CohnReznick, and elected three Class I directors.
- Tang Capital Partners provides limited guaranty up to $21.4M; support agreements covering ~5.1% of shares secured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/0001104659-25-057620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/tm2517439d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-057620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer